The Cost-Effectiveness of Personalized Genetic Medicine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Neonatal diabetes mellitus is a rare form of diabetes diagnosed in infancy. Nearly half of patients with permanent neonatal diabetes have mutations in the genes for the ATP-sensitive potassium channel (KCNJ11 and ABCC8) that allow switching from insulin to sulfonylurea therapy. Although treatment conversion has dramatic benefits, the cost-effectiveness of routine genetic testing is unknown. RESEARCH DESIGN AND METHODS: We conducted a societal cost-utility analysis comparing a policy of routine genetic testing to no testing among children with permanent neonatal diabetes. We used a simulation model of type 1 diabetic complications, with the outcome of interest being the incremental cost-effectiveness ratio (ICER, $/quality-adjusted life-year [QALY] gained) over 30 years of follow-up. RESULTS: In the base case, the testing policy dominated the no-testing policy. The testing policy was projected to bring about quality-of-life benefits that enlarged over time (0.32 QALYs at 10 years, 0.70 at 30 years) and produced savings in total costs that were present as early as 10 years ($12,528 at 10 years, $30,437 at 30 years). Sensitivity analyses indicated that the testing policy would remain cost-saving as long as the prevalence of the genetic defects remained >3% and would retain an ICER <$200,000/QALY at prevalences between 0.7 and 3%. CONCLUSIONS: Genetic testing in neonatal diabetes improves quality of life and lowers costs. This paradigmatic case study highlights the potential economic impact of applying the concepts of personalized genetic medicine to other disorders in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137 · cited 1×
“There is one report of a patient who has been stably treated with a sulfonylurea for more than 50 years since his diagnosis at age 12 weeks (3).”
BackgroundMolecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young
Fajans, S. S., Bell, G. I., & Polonsky, K. S. (2001) · New England Journal of Medicine · doi:10.1056/nejmra002168 · Cited by 1,123
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988
Activating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus
Babenko, A. P., Polak, M., Cavé, H., Busiah, K., Czernichow, P., Scharfmann, R., Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., & Froguel, P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055068 · Cited by 655
Insulin gene mutations as a cause of permanent neonatal diabetes
Støy, J., Edghill, E. L., Flanagan, S. E., Ye, H., Paz, V. P., Pluzhnikov, A., Below, J. E., Hayes, M. G., Cox, N. J., Lipkind, G. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707291104 · Cited by 564
Self-citationInsulin Mutation Screening in 1,044 Patients With Diabetes
Edghill, E. L., Flanagan, S. E., Patch, A.-M., Boustred, C., Parrish, A., Shields, B., Shepherd, M. H., Hussain, K., Kapoor, R. R., Malecki, M., et al. (2008) · Diabetes · doi:10.2337/db07-1405 · Cited by 397
Self-citationDiagnosis and treatment of neonatal diabetes: an United States experience†
Støy, J., Greeley, S. A. W., Paz, V. P., Ye, H., Pastore, A. N., Skowron, K. B., Lipton, R. B., Cogen, F. R., Bell, G. I., Philipson, L. H., et al. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00433.x · Cited by 126
Self-citationGirard, C. A., Wunderlich, F. T., Shimomura, K., Collins, S., Kaizik, S., Proks, P., Abdulkader, F., Clark, A., Ball, V., Zubcevic, L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35772 · Cited by 105 · cited 1×
“Mouse models support the hypothesis that such age-related decline in functional b-cell mass may occur in the absence of sulfonylurea “rescue” of healthy b-cell function (13).”
Background
Cited by
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319
“In NDM, genetic testing is actually cost-saving because of improved cheaper treatment; testing for MODY in appropriate populations can also be cost-effective.(24,25) Thus, comprehensive testing on appropriately selected patients is an increasingly costeffective approach that can provide a genetic diagnosis that predic…”
Self-citationPrecision diabetes: learning from monogenic diabetes
Hattersley, A. T., & Patel, K. A. (2017) · Diabetologia · doi:10.1007/s00125-017-4226-2 · Cited by 306
Greeley, S. A. W., Polak, M., Njølstad, P. R., Barbetti, F., Williams, R., Castano, L., Raile, K., Chi, D. V., Habeb, A., Hattersley, A. T., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13426 · Cited by 211
Self-citationThe diagnosis and management of monogenic diabetes in children and adolescents
Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N., Chi, D. V., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12192 · Cited by 196
Riddle, M. C., Philipson, L. H., Rich, S. S., Carlsson, A., Franks, P. W., Greeley, S. A. W., Nolan, J. J., Pearson, E. R., Zeitler, P. S., & Hattersley, A. T. (2020) · Diabetes Care · doi:10.2337/dci20-0065 · Cited by 117
Self-citation
Metadata
- Authors
- Greeley, S. A. W., John, P. M., Winn, A. N., Ornelas, J., Lipton, R. B., Philipson, L. H., Bell, G. I., & Huang, E. S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-02-17
- Volume
- 34
- Issue
- 3
- Pages
- 622-627
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2103285808
- Cited by
- 85
- References
- 9
- FWCI
- 17.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.